Eliaz Therapeutics, Inc.
Santa Rosa, CA · CIK 0002042609 · Medtech · Private
Immunoadsorption apheresis column that selectively depletes galectin-3 protein from blood to treat sepsis and acute kidney injury
eliaztherapeutics.com →- Grants
- $2.9M
- 3 awards
- Sector median: 1
- Raised
- $850K
- 1 Form D · Oct 2025
- 11 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 11 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Depleting Circulating Galectin-3 with Therapeutic Apheresis: A Novel Treatment for Sepsis/AKI. | $224,577 | |
| Federal grant | Department of Health and Human Services · Phase II · Depleting Circulating Galectin-3 with Therapeutic Apheresis: A NovelTreatment for Sepsis/AKI | $1,681,971 | |
| Federal grant | Department of Health and Human Services · Phase II · Depleting Circulating Galectin-3 with Therapeutic Apheresis: A NovelTreatment for Sepsis/AKI | $990,810 | |
| Private capital raised | Form D · SEC | $850,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1344 | Aethon Medical | — | — |
| 1345 | Simulated Inanimate Models LLC | — | $900K |
| 1346 | NOVOPYXIS INC. | — | $856K |
| 1347 | Eliaz Therapeutics, Inc. | — | $850K |
| 1348 | WNT SCIENTIFIC LLC | — | — |
| 1349 | Echopoint Medical Ltd | — | $250K |
| 1350 | Fresenius Medical Care Glendale, LLC | — | $216K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Isaac EliazDirector · Executive Officer
- Milton GossExecutive Officer
Patents
- Plasmapheresis Devicegranted
- Plasmapheresis Therapygranted
- Method for Treating Sepsisapplication
- GALECTIN-3 Plasmapheresis Therapygranted
- GALECTIN-3 Plasmapheresis Therapygranted
- GALECTIN-3 Plasmapheresis Therapygranted
- GALECTIN-3 Plasmapheresis Therapygranted
- Treatment Of Viral Infection By Apheresisapplication
- GALECTIN-3 Plasmapheresis Therapygranted
- Plasmapheresis Devicegranted
- Patient Selective Apheresisgranted
- GALECTIN-3 Plasmapheresis Therapygranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.